NIH Awards Grant to Enable Biosciences to Develop Improved Lyme Disease Test

NIH Awards Grant to Enable Biosciences to Develop Improved Lyme Disease Test

he National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded a one-year Phase I Small Business Innovative Research (SBIR) grant for $225,000 in funding to Enable Biosciences to develop an improved Lyme disease test.

Enable Biosciences Teams Up with Hamilton Robotics

Enable Biosciences Teams Up with Hamilton Robotics

Hamilton Company and Enable Biosciences are pleased to announce their collaboration to provide fully automated processing of up to 96 liquid biopsy samples at one time using a novel ultra-sensitive and highly specific immunoassay in a hands-free workflow. 

The Microlab STAR optimized for the ADAP assay technology will be co-promoted by Hamilton and Enable Biosciences, and a single, localized point of contact will enable researchers to seamlessly integrate the automated workflow into their laboratory, while leveraging the respective expertise and services of each Company.

Scientist Spotlight: Jordan Owyoung

Welcome to Enable Biosciences’ Scientist Spotlight, a semi-regular blog post highlighting one of our scientists working to bring Enable’s technology to fruition.

Tell us a little bit about yourself.

Hi all, I’m Jordan! I’m a Bay Area native who recently graduated from the University of California, Davis with a B.S. in Genetics and Genomics and a B.A. in Linguistics (go Ags!). At Davis, in addition to school, I also enjoyed being a member on the Division 1 NCAA Women’s Swim Team.

Scientist Spotlight: Kenneth Danh

Welcome to Enable Biosciences’ Scientist Spotlight, a semi-regular blog post highlighting one of our scientists working to bring Enable’s technology to fruition.

Tell us a little bit about yourself.

Greetings! My name is Kenneth Danh and I am a research associate at Enable Biosciences. I grew up in San Jose and went to school at University of California, San Diego (UCSD) for my BS degree in Animal Physiology and Neurosciences. Since then I have been a QC Validation Associate at a pharmaceutical manufacturer, a medical biller for a pain rehabilitation clinic, and a lab manager for an ophthalmology lab.

Scientist Spotlight: David Gebhart

Scientist Spotlight: David Gebhart

Welcome to Enable Biosciences’ Scientist Spotlight, a semi-regular blog post highlighting one of our scientists working to bring Enable’s technology to fruition.

Tell us a little bit about yourself.

My name is David Gebhart, and I am the assay development engineer at Enable Biosciences. I received my BS in Engineering from Olin College outside of Boston. Olin is a very small and relatively new college; I graduated as a part of only the 4th graduating class. This close-knit, scientifically-minded community prepared me to take on multifunctional roles in startups and small teams. Before Enable I worked building tissue-engineered blood vessels and then induced pluripotent stem cells.

Enable Biosciences Relocates to South San Francisco to Launch Clinical Testing Lab

Enable Biosciences Relocates to South San Francisco to Launch Clinical Testing Lab

San Francisco, CA, October 22, 2018 – Enable Biosciences Inc. has moved to a new location in South San Francisco to accommodate growth and to launch a new clinical testing facility.

Since  2016, Enable Biosciences has been housed at MBC Biolabs, a biotechnology incubator located in the Dogpatch neighborhood in San Francisco. Now a team of six scientists, engineers, and physicians, Enable plans to expand to include clinical scientists in anticipation of the launch of their blood and saliva tests for type 1 diabetes, lyme disease, and food allergy over the next year. The new facility spans 3,488 square feet over two floors, with refurbished lab facilities and office space.

Enable Biosciences Selected for NIH Commercial Accelerator Program

Enable Biosciences Selected for NIH Commercial Accelerator Program

Enable Biosciences has been selected from over 300 NIH Phase 2 grant awardees to participate in the 2018 - 2019 National Institutes of Health Commercial Accelerator Program (CAP). Per the NIH: “The CAP is well-regarded for its combination of deep domain expertise and access to industry connections which have resulted in measurable gains and accomplishments by participating companies.” The NIH further describes: “The program enables participants to establish market and customer relevance, build commercial relationships, and focus on revenue opportunities available to them.”